• Search results for SII
Image Title

Serum Institute to start manufacturing Sputnik vaccine in September 

Serum Institute of India (SII) will start production of Sputnik vaccine at the company's facilities in September, Russian Direct Investment Fund (RDIF) said on Tuesday

Published on 13th July 2021

Serum Institute of India begins manufacturing Covovax, trials for children to begin in July

SII's Phase-2 and 3 clinical trials of Covovax will reportedly be conducted in 920 children - 460 each in 12-17 years and 2-11 years groups, media reports said

Published on 26th June 2021

Serum Institute seeks DCGI nod to examine and manufacture Sputnik V in India

The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June

Published on 3rd June 2021

Serum prices COVID vaccine for Pvt hospitals at Rs 600/dose, for state govt at Rs 400/dose 

SII said the Covishield vaccine will be available to state governments for Rs 400 per dose and to private hospitals at Rs 600 per dose

Published on 21st April 2021

Serum Institute's second COVID vaccine likely to be launched in September

In August 2020, the two companies announced an agreement under which Novavax had given SII the licence to manufacture and supply the vaccine in low- and middle-income countries

Published on 27th March 2021

Serum Institute of India gets Oxford-AstraZeneca vaccine purchase order from Centre 

The SII vaccine developed by Oxford-AstraZeneca was cleared for emergency use along with Bharat Biotech's indigenous "Covaxin" earlier this month

Published on 11th January 2021

SII, Bharat Biotech's COVID-19 vaccines approved for restricted use in emergency situations

The SEC of Standard Drug Organisation met on 1st and 2nd Jan and made recommendations in respect of proposal of restructed emergency approval of COVID-19 vaccine of SII, according to DCGI

Published on 3rd January 2021

UK's Oxford vaccine Phase-2 trial indicates strong results in older adults, says Lancet study

The Oxford Covid-19 vaccine has collaborated with Indian drug maker--Serum Institute of India (SII) for which phase 2 clinical trials are being conducted in India also

Published on 19th November 2020

Serum Institute, ICMR complete enrolment in Phase III trials for COVID-19 vaccine

ICMR and SII have further collaborated for clinical development of another COVID-19 vaccine Covovax, which has been developed by Novavax, USA, and upscaled by SII

Published on 12th November 2020

Search results 1 - 9 of 45